Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | CNR2 | P34972 | 9/20 | 0.47 |
| ▸ | BCHE | P06276 | 7/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | EYA3 | Q99504 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068281 | 0.79 | L3MBTL1 (0.67) | L3MBTL1CNR2BCHEACHECNR1 | |
| SCHEMBL13049740 | 0.78 | L3MBTL1 (0.41) | L3MBTL1CYP2C19 | |
| SCHEMBL11734608 | 0.77 | L3MBTL1 (0.64) | L3MBTL1CNR2BCHEACHECNR1 | |
| SCHEMBL6583139 | 0.76 | L3MBTL1 (0.56) | L3MBTL1CNR2BCHEACHECNR1 | |
| SCHEMBL6586815 | 0.76 | L3MBTL1 (0.73) | L3MBTL1CNR2BCHECNR1CYP2C19 | |
| SCHEMBL11735500 | 0.75 | L3MBTL1 (0.92) | L3MBTL1CNR2BCHECNR1CYP2C19 | |
| SCHEMBL11673108 | 0.75 | CYP2C19 (0.64) | L3MBTL1CNR2BCHECNR1CYP2C19 | |
| SCHEMBL13049746 | 0.75 | KMT2A (0.42) | L3MBTL1CYP2C19 | |
| SCHEMBL13049757 | 0.75 | KMT2A (0.39) | L3MBTL1CYP2C19ATM | |
| SCHEMBL11727292 | 0.73 | L3MBTL1 (0.56) | L3MBTL1CNR2CNR1CYP2C19EYA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7837981-B2 | Methods for imaging soluble A-beta | GENERAL ELECTRIC COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1631561-B1 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID | GEN ELECTRIC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7727511-B2 | Agents for imaging soluble a-beta | GENERAL ELECTRIC COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727511-B2 | Agents for imaging soluble a-beta | GENERAL ELECTRIC COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070140960-A1 | METHODS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070140960-A1 | METHODS FOR IMAGING SOLUBLE A-BETA | APBA1, APP, FABP7 | L3MBTL1 1694/4885CNR2 2229/4885BCHE 333/4885 |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | APBA1, APP, FABP7 | L3MBTL1 2056/4885CNR2 2210/4885BCHE 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.